The DOI matches its Crossref record.
HIV inhibitory natural products. Part 7. The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum
Abstract
Eight new coumarin compounds (1-8) were isolated by anti-HIV bioassay-guided fractionation of an extract of Calophyllum lanigerum. The structures of calanolide A (1), 12-acetoxycalanolide A (2), 12-methoxycalanolide A (3), calanolide B (4), 12-methoxycalanolide B (5), calanolide C (6) and related derivatives 7 and 8 were solved by extensive spectroscopic analyses, particularly HMQC, HMBC, and difference NOE NMR experiments. The absolute stereochemistry of calanolide A (1) and calanolide B (4) was established by a modified Mosher's method. Calanolides A (1) and B (4) were completely protective against HIV-1 replication and cytopathicity (EC50 values of 0.1 microM and 0.4 microM, respectively), but were inactive against HIV-2. Some of the related compounds also showed evidence of anti-HIV-1 activity. Studies with purified bacterial recombinant reverse transcriptases (RT) revealed that the calanolides are HIV-1 specific RT inhibitors. Moreover, calanolide A was active not only against the AZT-resistant G-9106 strain of HIV-1 but also against the pyridinone-resistant A17 strain. This was of particular interest since the A17 virus is highly resistant to previously known HIV-1 specific, non-nucleoside RT inhibitors (e.g., TIBO; BI-RG-587; L693,593) which comprise a structurally diverse but apparently common pharmacologic class. The calanolides represent a substantial departure from the known class and therefore provide a novel new anti-HIV chemotype for drug development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The value of plants used in traditional medicine for drug discovery.
Fabricant, D. S., & Farnsworth, N. R. (2001) · Environmental Health Perspectives · doi:10.1289/ehp.01109s169 · Cited by 2,038
A Historical Overview of Natural Products in Drug Discovery
Dias, D. A., Urban, S., & Roessner, U. (2012) · Metabolites · doi:10.3390/metabo2020303 · Cited by 1,958
Drug discovery from medicinal plants
Balunas, M. J., & Kinghorn, A. D. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.012 · Cited by 1,810
Natural products to drugs: natural product-derived compounds in clinical trials
Butler, M. S. (2008) · Natural Product Reports · doi:10.1039/b514294f · Cited by 1,075
Review on Natural Coumarin Lead Compounds for Their Pharmacological Activity
Venugopala, K. N., Rashmi, V., & Odhav, B. (2013) · BioMed Research International · doi:10.1155/2013/963248 · Cited by 959
Nicolaou, K. C., Pfefferkorn, J. A., Roecker, A. J., Cao, G.-Q., Barluenga, S., & Mitchell, H. J. (2000) · Journal of the American Chemical Society · doi:10.1021/ja002033k · Cited by 678
Recent progress in the development of coumarin derivatives as potent anti‐HIV agents
Yu, D., Suzuki, M., Xie, L., Morris‐Natschke, S. L., & Lee, K. (2003) · Medicinal Research Reviews · doi:10.1002/med.10034 · Cited by 515
Natural products to drugs: natural product derived compounds in clinical trials
Butler, M. S. (2005) · Natural Product Reports · doi:10.1039/b402985m · Cited by 491
Plant-derived compounds in clinical trials
Saklani, A., & Kutty, S. K. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2007.10.010 · Cited by 477
Natural Product Drug Discovery in the Next Millennium
Cragg, G., & Newman, D. (2001) · Pharmaceutical Biology · doi:10.1076/phbi.39.7.8.5868 · Cited by 448
Self-citationTwenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go?
Mehellou, Y., & De Clercq, E. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm900492g · Cited by 368
De Clercq, E. (1998) · Antiviral Research · doi:10.1016/s0166-3542(98)00025-4 · Cited by 358
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection
De Clercq, E. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200009)20:5<323::aid-med1>3.0.co;2-a · Cited by 355
Anticancer activity of new coumarin substituted hydrazide–hydrazone derivatives
Nasr, T., Bondock, S., & Youns, M. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.02.026 · Cited by 334
Synthesis of Natural Product Inspired Compound Collections
Kumar, K., & Waldmann, H. (2009) · Angewandte Chemie International Edition · doi:10.1002/anie.200803437 · Cited by 301
Natural Coumarins: Exploring the Pharmacological Complexity and Underlying Molecular Mechanisms
Sharifi-Rad, J., Cruz-Martins, N., López-Jornet, P., Lopez, E. P.-F., Harun, N., Yeskaliyeva, B., Beyatli, A., Sytar, O., Shaheen, S., Sharopov, F., et al. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6492346 · Cited by 297
The Structure and Pharmacological Functions of Coumarins and Their Derivatives
Wu, L., Wang, X., Xu, W., Farzaneh, F., & Xu, R. (2009) · Current Medicinal Chemistry · doi:10.2174/092986709789578187 · Cited by 289
An evaluation of the antioxidant and antiviral action of extracts of rosemary and provençal herbs
Aruoma, O. I., Spencer, J. P. E., Rossi, R., Aeschbach, R., Khan, A., Mahmood, N., Munoz, A., Murcia, A., Butler, J., & Halliwell, B. (1996) · Food and Chemical Toxicology · doi:10.1016/0278-6915(96)00004-x · Cited by 288
HIV‐1 NNRTIs: structural diversity, pharmacophore similarity, and impliations for drug design
Zhan, P., Chen, X., Li, D., Fang, Z., De Clercq, E., & Liu, X. (2013) · Medicinal Research Reviews · doi:10.1002/med.20241 · Cited by 192
Metadata
- Authors
- Kashman, Y., Gustafson, K. R., Fuller, R. W., Cardellina, J. H., McMahon, J. B., Currens, M. J., Buckheit, R. W., Hughes, S. H., Cragg, G. M., & Boyd, M. R.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1992-07
- Volume
- 35
- Issue
- 15
- Pages
- 2735-2743
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2231831983
- Cited by
- 552
- References
- 0
- FWCI
- 12.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.